Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 45, 2014, Pages 15964-15968

  Bozic, Ivana ^a   Nowak, Martin A ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Cancer; Drug resistance; Heterogeneity; Mathematical biology

Indexed keywords

CHLOROPLAST DNA; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CLINICAL STUDY; COLORECTAL CANCER; COMPARATIVE STUDY; COMPUTER SIMULATION; DAUGHTER CELL; DRUG RESISTANCE; GENETIC HETEROGENEITY; HUMAN; METASTASIS; MUTATION RATE; POINT MUTATION; POPULATION SIZE; PREDICTION; PROBABILITY; TUMOR VOLUME; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; COLORECTAL NEOPLASMS; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; RADIOGRAPHY;

COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MODELS, GENETIC; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84909606346     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1412075111     Document Type: Article

References (35)

1. Vogelstein B, et al. (2013) Cancer genome landscapes. Science 339(6127):1546-1558.
2. Sawyers C (2004) Targeted cancer therapy. Nature 432(7015):294-297.
3. Michor F, et al. (2005) Dynamics of chronic myeloid leukaemia. Nature 435(7046):1267-1270.
4. Gerber DE, Minna JD (2010) ALK inhibition for non-small cell lung cancer: From discovery to therapy in record time. Cancer Cell 18(6):548-551.
5. Komarova NL, Wodarz D (2013) Targeted Cancer Treatment In Silico: Small Molecule Inhibitors and Oncolytic Viruses (Springer, New York).
6. Chapman PB, et al.; BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516.
7. Maemondo M, et al.; North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380-2388.
8. Katayama R, et al. (2011) Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 108(18):7535-7540.
9. Sosman JA, et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707-714.
10. Diaz LA, Jr, et al. (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486(7404):537-540.
11. Pao W, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73.
12. Antonescu CR, et al. (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11(11):4182-4190.
13. O'Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110(7):2242-2249.
14. Misale S, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404):532-536.
15. Bozic I, et al. (2013) Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2:e00747.
16. Coldman AJ, Goldie JH (1983) A model for the resistance of tumor cells to cancer chemotherapeutic agents. Math Biosci 65(2):291-307.
17. Iwasa Y, Nowak MA, Michor F (2006) Evolution of resistance during clonal expansion. Genetics 172(4):2557-2566.
18. Durrett R, Moseley S (2010) Evolution of resistance and progression to disease during clonal expansion of cancer. Theor Popul Biol 77(1):42-48.
19. Komarova NL, Wodarz D (2005) Drug resistance in cancer: Principles of emergence and prevention. Proc Natl Acad Sci USA 102(27):9714-9719.
20. Komarova N (2006) Stochastic modeling of drug resistance in cancer. J Theor Biol 239(3):351-366.
21. Haeno H, Iwasa Y, Michor F (2007) The evolution of two mutations during clonal expansion. Genetics 177(4):2209-2221.
22. Bozic I, Allen B, Nowak MA (2012) Dynamics of targeted cancer therapy. Trends Mol Med 18(6):311-316.
23. Luria SE, Delbrück M (1943) Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28(6):491-511.
24. Kessler DA, Levine H (2013) Large population solution of the stochastic Luria-Delbruck evolution model. Proc Natl Acad Sci USA 110(29):11682-11687.
25. Kessler DA, Levine H (2014) Scaling solution in the large population limit of the general asymmetric stochastic Luria-Delbrück evolution process. arXiv:1404.2407.
26. Foo J, Michor F (2014) Evolution of acquired resistance to anti-cancer therapy. J Theor Biol 355:10-20.
27. Bailey NTJ (1964) The Elements of Stochastic Processes With Applications to the Natural Sciences (Wiley, New York).
28. Leder K, et al. (2011) Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS ONE 6(11):e27682.
29. Bettegowda C, et al. (2014) Detection of circulating tumor DNA in early- and latestage human malignancies. Sci Transl Med 6(224):224ra24.
30. O'Connell N (1993) Yule process approximation for the skeleton of a branching process. J Appl Probab 30(3):725-729.
31. Manrubia SC, Zanette DH (2002) At the boundary between biological and cultural evolution: The origin of surname distributions. J Theor Biol 216(4):461-477.
32. Maruvka YE, Shnerb NM, Kessler DA (2010) Universal features of surname distribution in a subsample of a growing population. J Theor Biol 262(2):245-256.
33. Dewanji A, Luebeck EG, Moolgavkar SH (2005) A generalized Luria-Delbrück model. Math Biosci 197(2):140-152.
34. Athreya KB, Ney PE (1972) Branching Processes (Springer-Verlag, Berlin).
35. Gillespie DT (1977) Exact stochastic simulation of coupled chemical reactions. J Phys Chem 81(25):2340-2361.